Global MedTech Media InstituteSwitzerlandProfessional healthcare technology intelligence
Editor's Pick · Global
FDA selects Dexcom as first TEMPO digital health pilot participant, ushering in a new paradigm of AI-driven chronic disease management
FDA selects Dexcom as the first participant in the TEMPO Digital Health Pilot, which allows digital health devices to be exempt from certain premarket reviews while collecting real-world data. Dexcom will leverage AI and CGM technology to develop a blood glucose health program aimed at earlier intervention in diabetes. This initiative signals a significant shift in the U.S. healthcare regulatory and reimbursement system's attitude toward digital health, opening up new growth opportunities for the industry.
The application of artificial intelligence in the healthcare sector is moving from concept to scale. AI solutions launched by industry giants like Salesforce are transforming the delivery of medical services, but data privacy, regulatory compliance, and clinical validation remain major obstacles. In the next 3-5 years, AI is expected to achieve breakthroughs in personalized medicine and operational efficiency.
FDA selects Dexcom as the first participant in the TEMPO Digital Health Pilot, which allows digital health devices to be exempt from certain premarket reviews while collecting real-world data. Dexcom will leverage AI and CGM technology to develop a blood glucose health program aimed at earlier intervention in diabetes. This initiative signals a significant shift in the U.S. healthcare regulatory and reimbursement system's attitude toward digital health, opening up new growth opportunities for the industry.
The self-disinfecting medical equipment market is projected to reach $1.11 billion in 2026 and grow to $1.88 billion by 2030. North America leads the market, while Asia-Pacific is the fastest-growing region. Technological innovations such as UV-C and antimicrobial coatings are reshaping infection prevention and control standards.
AnalysisCMSMedical technology
Trending topics
Normalized tags help readers follow technology, disease areas, regulatory bodies and markets.
Regulatory Watch
Compliance changes by market
Track AI, device, reimbursement and privacy rules across major regions.
US FDA guidance
EU MDR updates
MENA tenders
AI & Data
Clinical data meets operations
Reporting on AI in diagnostics, imaging, hospital administration and drug research.
Model validation
Data governance
Workflow adoption
Devices & Wearables
Hardware with service economics
Coverage of connected devices, smart diagnostics and the global hardware market.
Remote monitoring
Robotics
Procurement
Biotech Pipeline
Life science innovation signals
Follow genomics, biopharma and precision medicine from research to market.
Genetic testing
Clinical evidence
Companion diagnostics
Market Moves
Companies, capital and partnerships
Concise context for founders, investors, BD teams and analysts.
Funding
M&A
Hospital partnerships
Countries
Global coverage with local context
Follow developments across Global, US, EU, China, MENA, LATAM and APAC.
Country tags
Regional policy
Market entry
Search by the way MedTech teams think
Filter by keyword, country, technology, disease area and publication time.
The U.S. FDA has announced that Dexcom is the first participant in its TEMPO Digital Health Pilot Program, which allows certain digital health devices to be exempt from premarket review while collecting real-world data through Medicare. Dexcom plans to use AI and continuous glucose monitoring technology to screen for prediabetes and type 2 diabetes, marking a deep integration of regulatory innovation and payment reform.
Heidi Health's "Pressure Points 2026" report shows that 83% of clinicians have already adopted ambient AI documentation tools on their own before their institutions establish formal AI governance frameworks, in response to the growing burden of medical documentation.
A joint survey by the American Medical Association (AMA) and Medscape shows that 97% of physicians at least occasionally review patient wearable device data, but fewer than 6% integrate it into clinical workflows. The lack of payment pathways, insufficient electronic health record integration, and concerns about legal liability and reliability are key barriers.
According to a sharing by Public Intelligence CEO Peter Julius on HIMSS TV, early trials of the social robot Hana-chan have shown that it can enhance patients' emotional well-being and help aggressive patients relax. This article analyzes the significance of this progress for the healthcare technology industry, the affected companies, and future trends.
Although smartwatch health data is becoming increasingly abundant, according to the latest survey by the American Medical Association (AMA), only 6% of doctors integrate it into their clinical workflow. Insurance reimbursement barriers, doubts about data authenticity, and difficulties in integrating with electronic health records are the main bottlenecks.